Zoetis(ZTS) Seeking Alpha·2025-03-11 17:00Company Performance - Zoetis reported an outstanding performance in 2024, achieving the second highest growth rate in its public company history [4] - The major franchises in companion animal products led the growth with double-digit increases [4] - Livestock products also showed consistent growth, increasing by 5% and 6% over the last two years [4] Industry Insights - The industry is characterized as incredibly resilient and still young, presenting substantial opportunities for expansion [4] - Zoetis holds a leadership position in existing markets such as dermatology and parasiticides, particularly with the Simparica franchise [4] - There is significant potential for growth in new markets, particularly in osteoarthritis (OA) pain management, where the company is just beginning to explore opportunities [4]